Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe

Published on:
April 28, 2022

In this new episode titled “Real-World Data to Support HTAs in Europe”, we will examine the various uses of Real-World Data (RWD) and how it is valued in Health Technology Assessments in multiple European nations. Learn more about using RWD as support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.

Meet our guests:

Catia Proenca – Director, Clinical Real-World Evidence, Alira Health 

Catia designs and manages Real-World Evidence strategies maintaining a Market Access perspective by ensuring key stakeholder needs (e.g., HTA, payers) are met, thus, maximizing access to innovation, and ultimately improving patient outcomes. With 13+ years of experience in industry and academia, Catia’s previous roles include positions at Wellmera, Novartis Global, and the Novartis Institute for Biomedical Research. Catia holds a Ph.D. in Neuroscience from the Weill Cornell Medical College, New York, and the University of Lisbon. 

Carsten Schwenke – HTA Expert

Carsten Schwenke is a licensed biostatistician and health economist, with a Ph.D. in public health, that has 25 years of experience in the pharmaceutical sector, focusing on clinical development and market access. He has been self-employed for the past 15 years, with a primary focus on the German HTA process. 

Meet our host:

Kenny Carberry – Director, Clinical Development, Alira Health 

Kenny leads business development efforts and initiatives for early-stage healthcare companies. His background covers various indications across pharma, medical devices, and digital health. In addition to his expertise in business development, Kenny has several years of experience in clinical trial operations and management. He offers a unique perspective on the clinical development lifecycle, from generating a comprehensive strategy to executing a successful trial. 


Related news

Publications September 20, 2023
UK HTA Approves TRANSLARNA (Ataluren) for Duchenne Muscular Dystrophy Citing Real-World Evidence
The NICE recommended routine funding for TRANSLARNA (ataluren) to treat Duchenne Muscular Dystrophy (DMD), based on RWE combined with feedback from patients, caregivers, and clinicians.
Real-World Evidence (RWE) RWE Decision Alert
News September 8, 2023
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Market Access Spain Startups
Publications August 21, 2023
French HTA Approves ZOKINVY (Lonafarnib) Based on Evidence Package Including RWE
ZOKINVY (lonafarnib) has been approved for reimbursement in France, and real-world evidence (RWE) played a key role in this decision.
Real-World Evidence (RWE) RWE Decision Alert
Events August 10, 2023
12th EPP Life Sciences Pricing Forum
We are excited to speak at the 12th EPP Life Sciences Pricing Forum for pricing directors and executives in Life Sciences.
EU Market Access
Events July 31, 2023
ESMO Congress
We are excited to join the ESMO Congress in Madrid. to disseminate the latest cutting-edge data for oncologists and other stakeholders.
Drug Development Market Access Oncology Spain
Events July 25, 2023
ERS International Congress
We're excited to join the ERS International Congress in Milan to explore the latest advances in respiratory medicine and science.
Italy Real-World Evidence (RWE)
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.